Integra Historical Cash Flow
| IART Stock | USD 24.12 0.60 2.43% |
Analysis of Integra LifeSciences cash flow over time is an excellent tool to project Integra LifeSciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 149.1 M or Other Non Cash Items of 18.7 M as it is a great indicator of Integra LifeSciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Integra LifeSciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Integra LifeSciences is a good buy for the upcoming year.
Integra |
About Integra Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Integra balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Integra's non-liquid assets can be easily converted into cash.
Integra LifeSciences Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Integra LifeSciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Integra LifeSciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Exchange Rate Changes
The impact of changes in foreign exchange rates on a company's financial position and results.Most accounts from Integra LifeSciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Integra LifeSciences' Begin Period Cash Flow is comparatively stable compared to the past year. Depreciation is likely to gain to about 149.1 M in 2025, whereas Free Cash Flow is likely to drop slightly above 67.3 M in 2025.
Integra LifeSciences cash flow statement Correlations
Click cells to compare fundamentals
Integra LifeSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Integra LifeSciences cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (48.3M) | 5.4M | (29.1M) | (59.8M) | (53.8M) | (51.1M) | |
| Change In Cash | 271.3M | 43.3M | (56.8M) | (180.3M) | (162.2M) | (154.1M) | |
| Free Cash Flow | 139.9M | 264.3M | 217.4M | 73.1M | 84.1M | 67.3M | |
| Change In Working Capital | (41.3M) | 18.2M | (39.4M) | (81.6M) | (73.4M) | (69.7M) | |
| Begin Period Cash Flow | 198.9M | 470.2M | 513.4M | 456.7M | 525.2M | 551.4M | |
| Other Cashflows From Financing Activities | 766.9M | 1.8M | (19.2M) | (9.4M) | (10.8M) | (10.3M) | |
| Depreciation | 116.0M | 119.8M | 118.3M | 123.5M | 142.0M | 149.1M | |
| Other Non Cash Items | 39.8M | (28.1M) | (18.1M) | 22.0M | 25.3M | 18.7M | |
| Capital Expenditures | 63.9M | 48.1M | 47.1M | 66.9M | 76.9M | 80.7M | |
| Total Cash From Operating Activities | 203.8M | 312.4M | 264.5M | 140.0M | 160.9M | 102.4M | |
| Net Income | 133.9M | 169.1M | 180.6M | 67.7M | 77.9M | 44.5M | |
| Total Cash From Financing Activities | 121.6M | (98.2M) | (252.0M) | (229.9M) | (264.4M) | (251.2M) | |
| End Period Cash Flow | 470.2M | 513.4M | 456.7M | 276.4M | 317.9M | 333.8M | |
| Sale Purchase Of Stock | (100M) | (4.8M) | (125M) | (275M) | (247.5M) | (235.1M) | |
| Stock Based Compensation | 19.6M | 36.2M | 27.7M | 20.1M | 23.2M | 16.6M | |
| Dividends Paid | 44.6M | 2.0M | 5.5M | 93.2M | 83.9M | 60.9M | |
| Other Cashflows From Investing Activities | (21.3M) | 79K | 16.1M | (1.0) | (1.15) | (1.21) | |
| Change To Account Receivables | 52.1M | 7.3M | (33.9M) | 4.6M | 4.1M | 4.3M | |
| Total Cashflows From Investing Activities | (162.7M) | (68.1M) | (161.4M) | (58.6M) | (52.7M) | (55.4M) | |
| Change To Netincome | 10.9M | (43.6M) | 126.4M | 2.2M | 2.5M | 2.4M | |
| Change Receivables | (9.4M) | 52.1M | 7.3M | (33.9M) | (30.5M) | (29.0M) | |
| Net Borrowings | (9.2M) | 281.2M | (100.2M) | (107.8M) | (97.0M) | (92.2M) | |
| Cash And Cash Equivalents Changes | 60.0M | 257.4M | 52.8M | (46.1M) | (53.0M) | (50.3M) | |
| Cash Flows Other Operating | 95.6M | 38.7M | (136K) | 13.6M | 15.6M | 16.4M | |
| Change To Liabilities | 12.6M | (60.4M) | 18.8M | 12.9M | 14.8M | 15.6M | |
| Investments | (7.8M) | 76K | 4.9M | (94.2M) | (84.8M) | (80.5M) | |
| Change To Operating Activities | 24.2M | 12.5M | (27.4M) | 2.0M | 1.8M | 2.1M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.